Hands-on experience in pharmaceutical policy shaping integrating regulatory and market access matters is what sets us apart from other agencies.

Oliver is a German qualified lawyer who works for over 25 years with the life sciences industry focusing on EU regulatory affairs, intellectual property and market access issues. He is providing strategic advice in policy matters at EU and Member States level.

Oliver has been a key driver in setting up a major pharmaceutical industry association at the EU level by building public affairs and policy capabilities for the organization.

With his longstanding experience in EU policy, Oliver is focusing on matters like the General Pharmaceutical Legislation and various other EU legislative procedures, representing industry needs in these processes but also by providing policy roadmaps and by organizing an effective stakeholder engagement for biopharmaceutical companies.

Matias has over 8 years’ experience advising biopharmaceutical companies in policy, market access and reimbursement matters. With a particular focus on the EU Health Technology Assessment (EU HTA) he supports various companies in navigating this new process.

Matias also has extensive expertise in the field of genomics and oncology matters by creating industry coalitions in both areas. Previously he has been working with the European Cancer Patient Coalition (ECPC) and the Norwegian Social Security Administration focusing on reimbursement of medical devices and coordination of social security within the EU/EEA.

Matias also covers market access for advanced diagnostics and use of Real-World Evidence by payers and HTA bodies and is following other current legislative initiatives such as the revision of the General Pharmaceutical Legislation and Europe’s Beating Cancer Plan.

Jean Louis brings 20 years of experience in the field of public health, government relations, patient engagement and rare diseases. A former public affairs director at EURORDIS, he represented the global rare disease community vis-a-vis European policymakers in Brussels like at the United Nations in New York, where he made early contributions to December 2021 General Assembly Résolution 76/132.

Over the past 10 years, Jean Louis has put his expertise and network at the service of two innovative biopharmaceutical companies, BioMarin and Ferring, where he built and grew focused and effective regional external affairs capabilities whilst supporting directly the business to deliver successful launches for several first-in-class pharmaceuticals, incl. gene and microbiome therapies.

On top of his substantive experience at the global and regional level, Jean Louis can also offer operational insights and strategic counsel across the many European local markets in which he has been active until very recently – from Spain to Finland or from Ireland to Italy. As a recent achievement, he is proud of having contributed to bringing to life the new National Plan against Infertility launched by the French Government in February 2026.